Bradykinin and endothelial-cardiac myocyte interactions in ischemic preconditioning

American Journal of Cardiology

Volumn 80, Issue 3 A, 1997, Pages 124A-131A

  Parratt, James R ^a,b,c   Vegh, Agnes ^a,b,c   Zeitlin, I Jack ^a,b,c   Ahmad, Maqsood ^a,b,c   Oldroyd, Keith ^a,b,c   Kaszala, Karoly ^a,b,c   Papp, Julius Gy ^a,b,c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BRADYKININ; BRADYKININ RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; METHYLENE BLUE; NITRIC OXIDE;

ANGIOPLASTY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL REACTIVITY; CELL INTERACTION; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOG; HEART MUSCLE ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; STIMULUS RESPONSE; VASCULAR ENDOTHELIUM;

EID: 0030762786     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00467-0     Document Type: Conference Paper

References (49)

1. Curtis MJ, Pugsley MK, Walker MJA. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res. 27:1993;703-719.
2. Parratt JR. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res. 27:1993;693-702.
3. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischaemic myocardium. Circulation. 74:1986;1124-1136.
4. Wainwright CL, Parratt JR. Myocardial preconditioning. 1996;Springer, Berlin.
5. Marber MS, Yellon DM. Ischaemia, preconditioning and adaptation. 1996;BIOS Scientific Publishers, Oxford.
6. Parratt JR. Protection of the heart by ischemic preconditioning: mechanisms and possibilities for pharmacologic exploitation. Trends Pharmacol Sci. 15:1994;19-25.
7. Parratt JR, Vegh A, Kaszala K, Papp J Gy. Protection by preconditioning and cardiac pacing against ventricular arrhythmias resulting from ischemia and reperfusion. Ann N Y Acad Sci. 793:1996;98-107.
8. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - a brief review of the evidence. Can J Physiol Pharmacol. 73:1995;837-842.
9. Parratt JR, Vegh A. Endothelial cells, nitric oxide and ischaemic preconditioning. Basic Res Cardiol. 91:1996;27-30.
10. Parratt JR. Eicosanoids and arrhythmogenesis. Vaughan-Williams EM. Antiarrhythmic Drugs. Handbook of Experimental Pharmacology. 89:1989;569-589 Berlin: Springer, Berlin.
11. Kimura E, Hashimoto K, Furakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J. 85:1973;635-647.
12. Hashimoto K, Hirose M, Furukawa S, Hayakawa H, Kimura E. Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J. 18:1977;679-689.
13. Marshall RJ, Parratt JR. The early consequences of myocardial ischaemia and their modification. J Physiol (Paris). 76:1980;699-715.
14. Pitt B, Mason J, Conti CR, Colman RW. Activation of the plasma kallikrein system during myocardial ischaemia. Adv Exp Med Biol. 8:1970;343-347.
15. Sicuteri F, Antonini FM, Del Bianco PL, Franchi G, Curradi C. Pre-kallikrein and kallikrein inhibitor in plasma of patients affected by recent myocardial infarction. Adv Exp Med Biol. 21:1972;445-449.
16. Hashimoto K, Hamamoto H, Honda Y, Hirose M, Furukawa S, Kimura E. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am Heart J. 95:1978;619-626.
17. Torstila I. Kallikrein-kinin system in myocardial ischaemia. Acta Med Scand Suppl. 620:1978;1-62.
18. Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol. 108:1993;293-295.
19. Koide A, Zeitlin IJ, Parratt JR. Kinin formation in ischaemic heart and aorta of anaesthetised rats. J Physiol. 467:1993;125P.
20. Ahmad M, Zeitlin IJ, Parratt JR, Kolar K. Kinin release from normally perfused and ischaemic isolated rat hearts: effect of strain. Immunopharmacology. 33:1996;297-298.
21. Ahmad M, Zeitlin IJ, Parratt JR. The release of kininase from rat isolated hearts during myocardial ischemia. Immunopharmacology. 33:1996;299-300.
22. Moshi MJ, Zeitlin IJ, Wainwright CL, Parratt JR. Acid optimum kininogenase in canine myocardium and aorta. Cardiovasc Res. 26:1992;367-370.
23. Ahmad M, Zeitlin IJ, Parratt JR, Valen G, Takeshima S, Vaage J. Changes in bradykinin levels in the blood of patients undergoing cardiopulmomary bypass (CPB). J Physiol. 494:1996;116P-117P.
24. Valen G, Takeshima S, Ahmad M, Zeitlin IJ, Parratt JR, Vaage J. Bradykinin in open heart surgery: metabolism of bradykinin in the coronary circulation during reperfusion. Exp Clin Cardiol (in press).
25. Vegh A, Szekeres L, Parratt JR. Protective effect of preconditioning of the ischaemic myocardium involves cyclooxygenase products. Cardiovasc Res. 12:1990;1020-1022.
26. Vegh A, Komori S, Szekeres L, Parratt JR. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res. 26:1992;487-495.
27. Parratt JR, Vegh A. Pronounced antiarrhythmic effects of ischemic preconditioning. Cardioscience. 55:1994;9-18.
28. Muller B, Kleschyov AL, Stoclet J-C. Evidence for N-acetylcysteine-sensitive nitric oxide storage as dinitrosyl-iron complexes in lipopolysaccharide-treated rat aorta. Br J Pharmacol. 119:1996;1281-1285.
29. Vegh A, Szekeres L, Parratt JR. Local coronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetised dogs. Br J Pharmacol. 104:1991;294-295.
30. Vegh A, Papp JGy, Szekeres L, Parratt JR. Prevention by an inhibitor of the L-arginine nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetised dogs. Br J Pharmacol. 110:1993;18-19.
31. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins, kallikreins, kininogens and kininases. Pharmacol Rev. 44:1992;1-80.
32. Parratt JR. Cardioprotection by angiotensin-converting enzyme inhibitors. Cardiovasc Res. 28:1994;183-189.
33. Wiemer G, Schölkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 28:1994;166-172.
34. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
35. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther. 270:1994;681-689.
36. Goto M, Liu Y, Yang X-M. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 77:1995;611-621.
37. Brew EC, Mitchell MB, Rehring TF. Role of bradykinin in cardiac functional protection after global ischaemia-reperfusion in rat heart. Am J Physiol. 269:1995;H1370-H1378.
38. 2 receptors. Br J Pharmacol; 113:1994;1167-1172.
39. Vegh A, Szekeres L, Parratt JR. Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol. 107:1992;648-652.
40. Vegh A, Papp JG, Szekeres L, Parratt JR. The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning. Br J Pharmacol. 107:1992;910-911.
41. Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M. Delayed effects of sublethal-ischemia on the acquisition of tolerance to ischaemia. Circ Res. 72:1993;1293-1299.
42. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation. 88:1993;1264-1272.
43. Vegh A, Papp JGy, Parratt JR. Prevention by dexamethasone of the marked antiarrhythmic effects of preconditioning induced 20 h after rapid cardiac pacing. Br J Pharmacol. 113:1994;1081-1082.
44. Parratt JR, Szekeres L. Delayed protection of the heart against ischaemia. Trends Pharmacol Sci. 16:1995;351-355.
45. Kaszala K, Vegh A, Papp JGy, Parratt JR. Time course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing. J Mol Cell Cardiol. 28:1996;2085-2095.
46. Kis A, Vegh A, Papp J Gy, Parratt JR. Repeated pacing widens the time window of delayed protection against ventricular arrhythmias in dogs. (Abstr.). J Mol Cell Cardiol. 28:1996;A229.
47. Vegh A, Kaszala K, Papp JGy, Parratt JR. Delayed myocardial protection by pacing-induced preconditioning: a possible role for bradykinin. Br J Pharmacol. 116:1995;288P.
48. 2 receptor blockade of protection by pacing against ischemia-induced arrhythmias. Eur J Pharmacol. 308:1997;51-60.
49. Fatehi-Hassanabad Z, Furman BL, Parratt JR. Endothelium and ischaemic preconditioning in rat isolated perfused hearts. J Physiol. 494:1996;112P-113P.